Epizyme, Inc.

NasdaqGS:EPZM Stock Report

Market Cap: US$247.5m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Epizyme Management

Management criteria checks 2/4

Key information

Grant Bogle

Chief executive officer

US$3.0m

Total compensation

CEO salary percentage9.9%
CEO tenure1yr
CEO ownershipn/a
Management average tenure2.3yrs
Board average tenure10.2yrs

Recent management updates

Recent updates

Epizyme GAAP EPS of -$0.21, revenue of $27.5M

Aug 09

Epizyme Acquisition By Ipsen: CVR Value

Jul 05

Some Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Made A Major Cut To Next Year's Estimates

May 16
Some Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Made A Major Cut To Next Year's Estimates

Epizyme: Taking Advantage Of Recent Sell-Off

Nov 25

Health Check: How Prudently Does Epizyme (NASDAQ:EPZM) Use Debt?

Sep 14
Health Check: How Prudently Does Epizyme (NASDAQ:EPZM) Use Debt?

Industry Analysts Just Made A Sizeable Upgrade To Their Epizyme, Inc. (NASDAQ:EPZM) Revenue Forecasts

Aug 10
Industry Analysts Just Made A Sizeable Upgrade To Their Epizyme, Inc. (NASDAQ:EPZM) Revenue Forecasts

Epizyme: Potential Comeback With Tazemetostat After Initial Sales Challenge

Jun 22

Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?

Jun 08
Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?

Epizyme gains as peer Constellation attracts sizable premium from MorphoSys

Jun 02

Epizyme, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 07

Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Trimmed Their Revenue Forecasts By 41%

Feb 25
Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Trimmed Their Revenue Forecasts By 41%

Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?

Jan 16
Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?

Epizyme says Boehringer terminates collaboration agreement

Dec 24

Would Shareholders Who Purchased Epizyme's (NASDAQ:EPZM) Stock Year Be Happy With The Share price Today?

Dec 12
Would Shareholders Who Purchased Epizyme's (NASDAQ:EPZM) Stock Year Be Happy With The Share price Today?

Epizyme Q3 2020 Earnings Preview

Nov 05

CEO Compensation Analysis

How has Grant Bogle's remuneration changed compared to Epizyme's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2022n/an/a

-US$208m

Mar 31 2022n/an/a

-US$236m

Dec 31 2021US$3mUS$299k

-US$251m

Sep 30 2021n/an/a

-US$267m

Jun 30 2021n/an/a

-US$257m

Mar 31 2021n/an/a

-US$251m

Dec 31 2020US$196kn/a

-US$232m

Sep 30 2020n/an/a

-US$222m

Jun 30 2020n/an/a

-US$202m

Mar 31 2020n/an/a

-US$192m

Dec 31 2019US$309kn/a

-US$173m

Compensation vs Market: Grant's total compensation ($USD3.01M) is above average for companies of similar size in the US market ($USD1.66M).

Compensation vs Earnings: Grant's compensation has increased whilst the company is unprofitable.

CEO

Grant Bogle (64 yo)

1yr

Tenure

US$3,011,807

Compensation

Mr. Grant C. Bogle has been Chief Executive Officer, President and Director at Epizyme, Inc. since August 9, 2021 and serves as Principal Financial Officer since November 1, 2021 and served as its Independ...

Leadership Team

NamePositionTenureCompensationOwnership
Grant Bogle
President1yrUS$3.01mno data
Jeffery Kutok
Chief Scientific Officer2.3yrsUS$2.86m0.0080%
$ 19.9k
H. Horvitz
Co-Founder & Chairman of the Scientific Advisory Boardno datano datano data
Yi Zhang
Scientific Co-Founder & Member of The Scientific Advisory Boardno datano datano data
Jerald Korn
Chief Operating Officerless than a yearno datano data
Joseph Beaulieu
Senior VP4.1yrsno data0.0058%
$ 14.3k
Craig West
Vice President of Investor Relationsno datano datano data
John Weidenbruch
Senior VPno datano datano data
Tanja Weber
Chief Business Officer3.6yrsno datano data
Mark De Rosch
Chief Regulatory Officer2.8yrsno datano data
Rebecca Mehrwerth
Senior VP & Head of Commercialless than a yearno datano data
Christoph Diefenbach
Laboratory Manager of Research & Developmentno datano datano data

2.3yrs

Average Tenure

56.5yo

Average Age

Experienced Management: EPZM's management team is considered experienced (2.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Grant Bogle
President2.9yrsUS$3.01mno data
H. Horvitz
Co-Founder & Chairman of the Scientific Advisory Boardno datano datano data
Yi Zhang
Scientific Co-Founder & Member of The Scientific Advisory Boardno datano datano data
George Daley
Member of the Scientific Advisory Boardno datano datano data
David Mott
Independent Chairman12.7yrsUS$370.00k0.19%
$ 474.0k
Carl Goldfischer
Independent Director12.9yrsUS$350.00k0.0030%
$ 7.4k
Christopher Walsh
Member of the Scientific Advisory Boardno datano datano data
Kenneth Bate
Independent Director7.7yrsUS$330.94k0%
$ 0
Bruce Chabner
Member of the Scientific Advisory Boardno datano datano data
Ronald Evans
Member of the Scientific Advisory Boardno datano datano data
Joel Huff
Member of the Scientific Advisory Boardno datano datano data
Steven Henikoff
Member of the Scientific Advisory Boardno datano datano data

10.2yrs

Average Tenure

68yo

Average Age

Experienced Board: EPZM's board of directors are seasoned and experienced ( 10.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2022/08/12 11:42
End of Day Share Price 2022/08/11 00:00
Earnings2022/06/30
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Epizyme, Inc. is covered by 16 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mohit BansalCitigroup Inc
Evan SeigermanCredit Suisse
Bradley CaninoCredit Suisse